When the immune system's master regulator goes rogue, disease follows. A new review reveals how dysregulation of NF-κB — a protein family controlling inflammation, immunity, and cell survival — underpins conditions from rheumatoid arthritis and IBD to cancer and rare immunodeficiencies. Researchers also map out promising therapeutic strategies, from existing biologics to next-gen nanoparticle and PROTAC-based delivery systems.
Think of NF-κB as the immune system's master control switch. When it works properly, it helps clear infections and repair tissue. When it misfires — either stuck in the "on" position or failing to activate — the consequences range from chronic inflammation to cancer to rare genetic immunodeficiencies.
A new comprehensive review published in Gene Expression breaks down the molecular machinery behind NF-κB signaling, including its two main pathways: the canonical pathway (rapid, transient, linked to inflammation and autoimmunity) and the non-canonical pathway (slower, sustained, critical for B-cell development and lymphoid tissue formation). Central to both are ubiquitin-based relay systems that act like molecular on/off switches — and when enzymes in these systems malfunction, disease follows.
The review also charts a roadmap for therapeutic intervention, noting that while indirect strategies like anti-TNF biologics and proteasome inhibitors are already approved, more precise tools — including NIK inhibitors, MALT1 blockers, and novel delivery platforms — are in development.
Key Takeaways:
Why it matters: NF-κB sits at the intersection of nearly every major inflammatory disease. A clearer understanding of its regulation — and how to selectively modulate it — could unlock more effective, less toxic treatments for millions of patients worldwide.
